Legal & General Group Plc Invests $389.09 Million in Edwards Lifesciences Corporation $EW

Legal & General Group Plc purchased a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, Holdings Channel reports. The firm purchased 4,301,222 shares of the medical research company’s stock, valued at approximately $389,089,000.

Several other large investors also recently bought and sold shares of the business. BlackRock Inc. purchased a new stake in shares of Edwards Lifesciences in the second quarter valued at about $5,318,092,000. Norges Bank purchased a new position in Edwards Lifesciences during the fourth quarter worth about $803,686,000. Conway Capital Management Inc. acquired a new position in Edwards Lifesciences in the 2nd quarter valued at about $954,000. Varma Mutual Pension Insurance Co acquired a new position in Edwards Lifesciences in the 2nd quarter valued at about $11,168,000. Finally, TD Asset Management Inc boosted its holdings in Edwards Lifesciences by 6.4% in the 4th quarter. TD Asset Management Inc now owns 778,129 shares of the medical research company’s stock valued at $66,335,000 after purchasing an additional 47,051 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Activity at Edwards Lifesciences

In other news, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the completion of the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel J. Lippis sold 619 shares of the firm’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,425 shares of company stock valued at $219,199 in the last quarter. 0.31% of the stock is owned by insiders.

Edwards Lifesciences Price Performance

Shares of EW opened at $90.92 on Wednesday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The stock has a market cap of $52.35 billion, a PE ratio of 52.25, a P/E/G ratio of 2.37 and a beta of 0.85. The firm has a 50-day simple moving average of $89.35 and a two-hundred day simple moving average of $84.82. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.52 and a quick ratio of 3.77.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same period in the previous year, the firm earned $0.67 EPS. The business’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on EW. BTIG Research raised their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Truist Financial upped their price objective on Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a report on Thursday, July 16th. Piper Sandler reiterated an “overweight” rating and issued a $101.00 price objective (up from $100.00) on shares of Edwards Lifesciences in a research report on Friday, July 24th. Citigroup increased their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Finally, Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Seventeen investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.